Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium
Title:
Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium
Author:
Li, Ling Xu-Monette, Zijun Y. Ok, Chi Y. Manyam, Ganiraju C. Visco, Carlo Tzankov, Alexander Montes-Moreno, Santiago Dybkær, Karen Chiu, April Orazi, Attilio Zu, Youli Bhagat, Govind Richards, Kristy L. Hsi, Eric D. Choi, William W.L. Han van Krieken, J. Huh, Jooryung Ponzoni, Maurilio Ferreri, Andrés J.M. Farnen, John P. Møller, Michael B. Piris, Miguel A. Winter, Jane N. Medeiros, L. Jeffrey Young, Ken H.